July 2, 2018

BioCentury

Defining access potential – Before it’s too late

Confirmation bias: when innovators believe in a drug, find the evidence to support its value, and dismiss or ignore the facts challenging their preferred story. Industry and its investors need a clear, objective lens through which they can burn away confirmation bias and see the likely access barriers their drugs will face once approved

June 18, 2018

Depression Rising (Again): Turning the Corner in Psychiatry’s Most Burdensome Disorder

For all of the millions who suffer from depression, the biological underpinnings of clinical depression are still not fully understood. With several high profile approval decisions and possible launches on the horizon, the stage is thus set for an emerging commercial case characterized by a new wave of effective anti-depressants, an increasingly influential assortment of payers and practitioners with generic but often ineffectual pharmacotherapy options at their disposal, and of course patients with an unabating level of need and strikingly high placebo response-rates. How will it play out?

March 26, 2018

“Manufacturers are realizing that this is going to be a feature of the landscape and some have begun to think about it as a mutual opportunity.” Steven Pearson, ICER

The Institute for Clinical and Economic Review is rapidly becoming the closest thing the U.S. has to an HTA agency. The credibility afforded by ICER’s independent status, and its inclusion of diverse stakeholder views in constructing its cost effectiveness analyses, are leading payers and PBMs to use the analyses to establish coverage criteria, determine formulary placement and negotiate discounts from drug manufacturers.

February 20, 2018

Harvard Pilgrim and Illumina sign first-of-its-kind value-based contract

Real Endpoints plays a valuable role in orchestrating a first-of-its-kind value-based contract between Harvard Pilgrim and Illumina by introducing the parties and helping to craft the deal structure. Real Endpoints will provide all analytics and financial reconciliation for the initiative.

January 11, 2018

Ophthalmology Innovation Summit

Drug Pricing Pro Roger Longman of Real Endpoints Says Spark Therapeutics Is Making the Right Moves

Roger Longman, CEO of Real Endpoints, a firm assisting pharma companies with their pricing strategies, discusses the state of the value-based pricing market while lending some insights on what specialty drug companies like Spark can do to get payers on board with higher prices.

May 16, 2017

BioCentury

Contracting 2.0: The Why, When, How — And Why Not — Of Value-Based Deals

Learn why are we are seeing increasing numbers of value-based deals in the industry, how they are structured and when they make sense.

May 3, 2017

Real Endpoints' White Paper

Preferences in MS Therapy: White Paper and Literature Review

Real Endpoints, LLC (RE), a data and analytics firm that assesses and quantifies pharmaceutical value, just published a white paper and extensive literature review to tease out how different stakeholder groups (patients, payers and physicians) assess the value of current multiple sclerosis (MS) therapies.

July 31, 2016

In Vivo

Smart Segmentation/ Success In The Payer-Dominated Pharma Marketplace

As physicians lose decision-making authority to payers, drug companies need to segment markets more effectively: the patient populations prescribers are most likely to treat and that will spark the fewest access battles; and the specific payer lines-of-business least inclined to block new drugs’ use.